Dermatology News and Research

Latest Dermatology News and Research

Preliminary results from Phase III study of afamelanotide in EPP announced

Clinuvel Pharmaceuticals Limited today announced that it has obtained promising 4-months results in testing afamelanotide in a multicentre randomised double-blind placebo controlled Phase III study in EPP (CUV017).

21 Dec 2009

Suneva Medical and WTI sign credit agreement to expand growth objectives

Suneva Medical, a privately-held aesthetic medical device company, today announced that it has signed a multi-million dollar line of credit facility with Western Technology Investment (WTI).

17 Dec 2009

Forest Laboratories Holdings and Almirall to develop, market and distribute LAS100977 in the US

Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. and Almirall, S.A. (ALM.MC) today announced that they have entered an agreement to develop, market and distribute LAS100977 in the United States.

17 Dec 2009

AAD's National Melanoma/Skin Cancer Screening Program reaches milestone

One person dies from melanoma, the deadliest form of skin cancer, almost every hour. Yet melanoma is often successfully treated, if caught early. That's why thousands of dermatologists across the country offer free skin cancer screenings in their communities through the American Academy of Dermatology's (AAD) National Melanoma/Skin Cancer Screening Program.

17 Dec 2009

Positive results from Onset Therapeutics' BenzEFoam Emollient Foam skin moisturization study

Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, today announced positive results from a skin moisturization study that compared the Company’s recently launched BenzEFoam™ (benzoyl peroxide 5.3%) Emollient Foam to a market leading combination gel containing clindamycin 1% - benzoyl peroxide 5%. BenzEFoam™ Emollient Foam is indicated for the topical treatment of mild to moderate acne vulgaris and is the first prescription foam formulation containing benzoyl peroxide as the active ingredient.

16 Dec 2009

Warner Chilcott begins cash tender offer

Warner Chilcott plc today announced that its subsidiary Warner Chilcott Corporation (the "Company") has commenced a cash tender offer, on the terms and subject to the conditions set forth in the Company's Offer to Purchase and Consent Solicitation Statement dated December 15, 2009 (the "Offer to Purchase"), for any and all of its outstanding 8.75% senior subordinated notes due 2015 (the "Notes").

16 Dec 2009

Zecotek Photonics' proprietary TGFL selected for research in flow cytometry

Zecotek Photonics Inc., a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the National Cancer Institute, a division of the U.S. National Institutes of Health (NIH), has selected its proprietary Tunable Green Fiber Laser (TGFL) for research in flow cytometry.

16 Dec 2009

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

Researchers at the Los Angeles Biomedical Research Institute (LA BioMed) expect to receive more than $4.5 million in grants from the American Recovery and Reinvestment Act (Recovery Act.), including nearly $1 million from the highly competitive Challenge Grant program for a study that seeks to reduce the number of children who die from Sudden Infant Death Syndrome, it was announced today.

15 Dec 2009

Scientists develop new model of skin cancer based on Src kinases

Scientists at the University of Pennsylvania School of Medicine have developed a new model of skin cancer based on the knowledge that a common cancer-related molecule called Src kinase is activated in human skin-cancer samples.

11 Dec 2009

JMC receives NIH grant to establish center of excellence for autoimmune diseases

The Department of Neurology at Jefferson Medical College (JMC) of Thomas Jefferson University has been awarded a multi-million dollar grant from the National Institutes of Health (NIH) for the creation of a center of excellence to study autoimmune diseases from basic science research to its translation into clinical applications.

10 Dec 2009

Nightingale Informatix to provide its EMR system to Uptown Health Centre

Nightingale Informatix Corporation, an application service provider (ASP) of electronic medical record (EMR) software and related services, announced today that it has been selected to provide its electronic medical record (EMR) system hosted at eHealth Ontario to all three Uptown Health Centre locations.

8 Dec 2009

New data from NanoBio's nanoemulsion-based adjuvant platform to be presented

NanoBio Corporation announced today that its CEO and Founder, James R. Baker, Jr., M.D., will present new data from studies of its nanoemulsion-based adjuvant platform during the World Influenza Congress, taking place from December 7-9, 2009 in Brussels, Belgium.

8 Dec 2009

CDA launches Acne And Rosacea Awareness Campaigns

The temperature drop outside is leaving many Canadians red in the face but dermatologists say the culprit could be acne or rosacea. The Canadian Dermatology Association (CDA) is launching Acne and Rosacea Awareness Campaigns to give sufferers the advice they need to cope with these diseases.

8 Dec 2009

ICON, CMFT collaborate to develop translational medicine facilities on the MRI campus

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced details of its new translational medicine unit in Manchester, UK. The unit is the first deliverable from a collaborative agreement between ICON and the Central Manchester University Hospitals Foundation (CMFT) to develop purpose-built translational medicine facilities on the newly-developed Manchester Royal Infirmary (MRI) campus.

7 Dec 2009

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester’s registration study in cutaneous T-cell lymphoma (CTCL) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

7 Dec 2009

Benchmark Physical Therapy selects Dynatronics as sole-source vendor

Dynatronics Corporation announced it has signed a sole-source vendor agreement to provide therapy equipment and rehab supplies to Benchmark Physical Therapy with 65 clinics located in Tennessee and Georgia.

5 Dec 2009

Text messaging technology has important implications for public health initiatives, finds study

A recent study conducted by the Center for Connected Health, a division of Partners HealthCare, found that text messaging is an innovative, low-cost and effective way to improve the daily use of sunscreen, and this technology may have important implications for larger-scale public health initiatives.

4 Dec 2009

AAD SEAL OF RECOGNITION program to be phased out

The American Academy of Dermatology (AAD) has decided to phase out its AAD SEAL OF RECOGNITION(R) program over the next two years, and will cease accepting new applications effective immediately. Products which were accepted into the program prior to November 15, 2009, will continue to carry the AAD SEAL OF RECOGNITION(R) until the end of their two-year terms.

3 Dec 2009

Positive results from NanoBio's recombinant H5N1 flu antigen-nanoemulsion vaccine combination study

NanoBio Corporation today announced positive results from studies in mice in which immune responses were evaluated following administration of 5µg doses of recombinant H5N1 pandemic flu antigen combined with the company’s novel nanoemulsion vaccine. These studies are unique because the adjuvant was administered for the first time by subcutaneous (SC) and intramuscular (IM) injections.

3 Dec 2009

Positive results from DermaGen's Phase I/IIa AMP study of atopic dermatitis

DermaGen AB - part of the Karolinska Development dermatology and wound healing company "Pergamum" - announced that Dermagen AB has received promising results from a clinical Phase I/IIa study. DermaGen AB is developing a novel antimicrobial peptide (AMP) treatment for atopic dermatitis. Atopic dermatitis is a chronic inflammatory skin disease where dry skin and the skin's weakened barrier function make patients susceptible to colonization by microorganisms, a triggering or exacerbating factor of the disease.

2 Dec 2009

Dermatology News and Research

Latest Dermatology News and Research

Preliminary results from Phase III study of afamelanotide in EPP announced

Suneva Medical and WTI sign credit agreement to expand growth objectives

Forest Laboratories Holdings and Almirall to develop, market and distribute LAS100977 in the US

AAD's National Melanoma/Skin Cancer Screening Program reaches milestone

Positive results from Onset Therapeutics' BenzEFoam Emollient Foam skin moisturization study

Warner Chilcott begins cash tender offer

Zecotek Photonics' proprietary TGFL selected for research in flow cytometry

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

Scientists develop new model of skin cancer based on Src kinases

JMC receives NIH grant to establish center of excellence for autoimmune diseases

Nightingale Informatix to provide its EMR system to Uptown Health Centre

New data from NanoBio's nanoemulsion-based adjuvant platform to be presented

CDA launches Acne And Rosacea Awareness Campaigns

ICON, CMFT collaborate to develop translational medicine facilities on the MRI campus

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Benchmark Physical Therapy selects Dynatronics as sole-source vendor

Text messaging technology has important implications for public health initiatives, finds study

AAD SEAL OF RECOGNITION program to be phased out

Positive results from NanoBio's recombinant H5N1 flu antigen-nanoemulsion vaccine combination study

Positive results from DermaGen's Phase I/IIa AMP study of atopic dermatitis

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Dermatology News and Research

Latest Dermatology News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in